RecruitingPhase 3NCT05918302
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Studying Neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
- Principal Investigator
- Jaume Capdevila, M.D. Ph.D.Hospital Vall d'Hebron
- Intervention
- 177Lu-edotreotide(drug)
- Enrollment
- 120 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2028
Study locations (27)
- Antwerp University Hospital (UZA), Edegem, Edegem, Belgium
- UCL Saint-Luc, Brussels, Belgium
- CHU Liège, Liège, Belgium
- Hospital Center University Dijon Bourgogne (CHU Bourgogne), Dijon, Dijon, France
- Centre Hospitalier Universitaire (CHU) Bordeux, Bourdeaux, France
- Lille University Hospital, Lille, France
- Hôpital Edouard Herriot, Lyon, Lyon, France
- Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France, Marseille, France
- Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier, Montpellier, France
- Centre Hospitalier Universitaire de Nantes, Nantes, France
- I. Gustave Roussy, Paris, Paris, France
- Azienda USL IRCCS Di Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy
- AOU Consorziale Policlinico di Bari - CROB Referrall Cancer Center of Basilicata, Bari, Italy
- IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Irsì - Meldola, Meldola, Italy
- Istituto Europeo di Oncologia - Milano, Milan, Italy
- +12 more locations on ClinicalTrials.gov
Collaborators
ITM Oncologics GmbH · MFAR
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05918302 on ClinicalTrials.govOther trials for Neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06202066Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine CarcinomasRoswell Park Cancer Institute
- RECRUITINGNCT06282016Risk Factors for Neuroendocrine NeoplasmsBavarian Cancer Registry
- RECRUITINGPHASE2NCT07077551NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm TrialSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06276309Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine TumorsFujian Maternity and Child Health Hospital
- RECRUITINGNCT06402695Observational Study on GEP-and Pulm-NET Treated at FPGFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE2NCT05879055A Study of PM8002 in Combination With Chemotherapy in Patients With NENBiotheus Inc.
- RECRUITINGNCT06337760YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.European Institute of Oncology
- RECRUITINGNANCT06523582Genetic Bases of Neuroendocrine Neoplasms in Mexican PatientsUniversidad Nacional Autonoma de Mexico